Home › Companies › REVOLUTION MEDICINES INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and REVOLUTION MEDICINES INC.’s Form 8-K, filed June 24, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 20, 2024: 5 items on REVOLUTION MEDICINES INC.’s Form 8-K, filed June 24, 2024: 2 approved · 3 passed (calculated).
Meeting of November 8, 2023: 2 items on REVOLUTION MEDICINES INC.’s Form 8-K, filed November 9, 2023: 2 approved.
Significant dissent: 1 director (25.4% against).
Notable dissent: 2 directors (17.9%, 17.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore REVOLUTION MEDICINES INC. in the interactive database Compare manager voting policies
These tallies are REVOLUTION MEDICINES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. REVOLUTION MEDICINES INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth McKee Anderson | 107,146,109 | -- | -- | 23,367,071 | 17,669,340 | 82% | Passed (calculated) | — |
| Elect Director: Flavia Borellini, Ph.D. | 107,339,633 | -- | -- | 23,173,547 | 17,669,340 | 82% | Passed (calculated) | — |
| Elect Director: Lorence Kim, M.D. | 97,387,991 | -- | -- | 33,125,189 | 17,669,340 | 75% | Passed (calculated) | — |
| 2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 | 148,105,275 | 9,895 | 67,350 | -- | -- | 99.9% | Approved | — |
| 3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC | 128,861,403 | 1,624,748 | 27,029 | -- | 17,669,340 | 99% | Approved | — |
This meeting is also recorded here as June 19, 2024; both records come from the same filing, so the date should be checked against it.
Source: REVOLUTION MEDICINES INC., Form 8-K, filed with the SEC on June 24, 2024 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant to Merger Agreement (the "Share Issuance | 85,738,003 | 9,442,157 | 123,934 | -- | -- | 90% | Approved | — |
| 2. Approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Share Issuance Proposal (the "Adjourn | 84,603,257 | 10,566,409 | 134,428 | -- | -- | 89% | Approved | — |
Source: REVOLUTION MEDICINES INC., Form 8-K, filed with the SEC on November 9, 2023 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
247 asset managers disclosed a vote on at least one REVOLUTION MEDICINES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held June 20, 2024.
Combines 4 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Flavia Borellini, Ph.D.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Flavia Borellini, Ph.D.”): 107,339,633 for, 23,173,547 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 44,383,531 for, 62 against, 8,515,056 withheld, 430,136 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,232,107 | 0 | 0 | 0 | For |
| BlackRock | 6,608,389 | 0 | 0 | 0 | For |
| Fidelity | 5,792,108 | 0 | 0 | 1,400 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,734,343 | Withhold |
| State Street | 2,349,129 | 0 | 0 | 3,240 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 2,192,696 | Withhold |
| JPMorgan | 2,096,349 | 0 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 826,675 | Withhold |
| Hartford | 758,858 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 708,697 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 650,826 | 0 | 0 | 0 | For |
| Victory Capital | 2,257 | 0 | 0 | 459,383 | Withhold |
| Equitable | 214,272 | 0 | 0 | 174,336 | Mixed |
| TIAA | 363,923 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 272,401 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 260,003 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 34,475 | 0 | 186,843 | 0 | Mixed |
| John Hancock | 88,806 | 0 | 111,039 | 0 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 183,868 | Withhold |
| Voya | 164,067 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,888 | 0 | 0 | 0 | For |
| Lincoln Financial | 135,547 | 0 | 0 | 5,214 | For |
| Jackson National | 0 | 0 | 120,029 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 0 | 115,256 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Meeting held June 20, 2024.
Combines 4 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Lorence Kim, M.D.
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Lorence Kim, M.D.”): 97,387,991 for, 33,125,189 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 38,833,073 for, 62 against, 14,061,841 withheld, 433,809 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,232,107 | 0 | 0 | 0 | For |
| BlackRock | 6,608,389 | 0 | 0 | 0 | For |
| Fidelity | 2,924,694 | 0 | 0 | 2,868,814 | Mixed |
| T. Rowe Price | 0 | 0 | 0 | 3,734,343 | Withhold |
| State Street | 2,436 | 0 | 0 | 2,349,933 | Withhold |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 2,192,696 | Withhold |
| JPMorgan | 2,096,349 | 0 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 826,675 | Withhold |
| Hartford | 758,858 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 708,697 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 650,826 | 0 | 0 | 0 | For |
| Victory Capital | 2,257 | 0 | 0 | 459,383 | Withhold |
| Equitable | 214,272 | 0 | 0 | 174,336 | Mixed |
| TIAA | 363,923 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 272,401 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 260,003 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 34,475 | 0 | 186,843 | 0 | Mixed |
| John Hancock | 88,806 | 0 | 111,039 | 0 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 183,868 | Withhold |
| Voya | 0 | 0 | 0 | 164,067 | Withhold |
| Northwestern Mutual | 152,888 | 0 | 0 | 0 | For |
| Lincoln Financial | 21,435 | 0 | 0 | 119,326 | Mixed |
| Jackson National | 0 | 0 | 120,029 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 0 | 115,256 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Meeting held June 20, 2024.
Combines 3 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect three Class I directors to hold office until the 2027 Annual Meeting of Stockholders or until his or her successor is elected: Elizabeth McKee Anderson
REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Elizabeth McKee Anderson”): 107,146,109 for, 23,367,071 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 44,383,531 for, 62 against, 8,515,056 withheld, 430,136 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,232,107 | 0 | 0 | 0 | For |
| BlackRock | 6,608,389 | 0 | 0 | 0 | For |
| Fidelity | 5,792,108 | 0 | 0 | 1,400 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,734,343 | Withhold |
| State Street | 2,349,129 | 0 | 0 | 3,240 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 2,192,696 | Withhold |
| JPMorgan | 2,096,349 | 0 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 826,675 | Withhold |
| Hartford | 758,858 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 708,697 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 650,826 | 0 | 0 | 0 | For |
| Victory Capital | 2,257 | 0 | 0 | 459,383 | Withhold |
| Equitable | 214,272 | 0 | 0 | 174,336 | Mixed |
| TIAA | 363,923 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 272,401 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 260,003 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 34,475 | 0 | 186,843 | 0 | Mixed |
| John Hancock | 88,806 | 0 | 111,039 | 0 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 183,868 | Withhold |
| Voya | 164,067 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,888 | 0 | 0 | 0 | For |
| Lincoln Financial | 135,547 | 0 | 0 | 5,214 | For |
| Jackson National | 0 | 0 | 120,029 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 0 | 115,256 | Withhold |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Meeting held November 8, 2023.
Combines 3 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRX, Inc., which is referred to as EQRX, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., Equinox Merger Sub II LLC, and EQRX, which proposal is referred to as the Revolution Medicines share issuance proposal; and
REVOLUTION MEDICINES INC.’s own tally for this item (“1. Approval of the issuance of shares of Revolution Medicines Common Stock (including securities convertible into or exercisable for shares of Revolution Medicines Common Stock) to certain equityholders of EQRx pursuant ”): 85,738,003 for, 9,442,157 against — passed, per its Form 8-K filed November 9, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Share Issuance Proposal was approved by the requisite vote of Revolution Medicines' stockholders.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 29,507,898 for, 6,750,721 against, 113,520 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,377,283 | 5,942,785 | 0 | 0 | Mixed |
| T. Rowe Price | 3,884,643 | 0 | 0 | 0 | For |
| BlackRock | 3,596,886 | 0 | 0 | 0 | For |
| Fidelity | 2,424,195 | 0 | 0 | 0 | For |
| JPMorgan | 2,202,536 | 0 | 0 | 0 | For |
| State Street | 1,895,188 | 0 | 0 | 0 | For |
| Dimensional | 1,401,752 | 0 | 0 | 0 | For |
| Charles Schwab | 764,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 714,722 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 500,650 | 0 | 0 | 0 | For |
| Hartford | 0 | 492,599 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 361,000 | 0 | 0 | 0 | For |
| Victory Capital | 312,928 | 1,962 | 0 | 0 | For |
| Equitable | 182,157 | 0 | 113,520 | 0 | Mixed |
| TIAA | 274,945 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 266,439 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 168,884 | 0 | 0 | 0 | For |
| John Hancock | 95,282 | 40,333 | 0 | 0 | Mixed |
| Brighthouse | 102,159 | 19,732 | 0 | 0 | Mixed |
| Northwestern Mutual | 0 | 117,269 | 0 | 0 | Against |
| Lincoln Financial | 110,733 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 107,663 | 0 | 0 | 0 | For |
| Jackson National | 91,021 | 0 | 0 | 0 | For |
| First Trust | 86,234 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 0 | 71,868 | 0 | 0 | Against |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Meeting held November 8, 2023.
Combines 2 wordings of this item as funds reported it.
89% Approved · of votes cast
Description as filed by funds: To approve the adjournment of the Revolution Medicines special meeting, to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal.
REVOLUTION MEDICINES INC.’s own tally for this item (“2. Approval of the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve t”): 84,603,257 for, 10,566,409 against — passed, per its Form 8-K filed November 9, 2023 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Adjournment Proposal was approved by the requisite vote of Revolution Medicines' stockholders, but no adjournment of this Special Meeting to solicit additional proxies was required or occurred.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 64 asset managers below reported 28,344,891 for, 7,902,667 against, 124,581 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 15,320,068 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,884,643 | 0 | 0 | Against |
| BlackRock | 3,596,886 | 0 | 0 | 0 | For |
| Fidelity | 576,453 | 1,847,742 | 0 | 0 | Mixed |
| JPMorgan | 2,202,536 | 0 | 0 | 0 | For |
| State Street | 0 | 1,895,188 | 0 | 0 | Against |
| Dimensional | 1,401,752 | 0 | 0 | 0 | For |
| Charles Schwab | 764,371 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 714,722 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 500,650 | 0 | 0 | 0 | For |
| Hartford | 492,599 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 361,000 | 0 | 0 | 0 | For |
| Victory Capital | 314,890 | 0 | 0 | 0 | For |
| Equitable | 162,009 | 20,148 | 113,520 | 0 | Mixed |
| TIAA | 274,945 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 266,439 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 168,884 | 0 | 0 | 0 | For |
| John Hancock | 79,377 | 56,238 | 0 | 0 | Mixed |
| Brighthouse | 53,335 | 68,556 | 0 | 0 | Mixed |
| Northwestern Mutual | 117,269 | 0 | 0 | 0 | For |
| Lincoln Financial | 28,333 | 82,400 | 0 | 0 | Mixed |
| Direxion Shares ETF Trust | 107,663 | 0 | 0 | 0 | For |
| Jackson National | 91,021 | 0 | 0 | 0 | For |
| First Trust | 86,234 | 0 | 0 | 0 | For |
| MML SERIES INVESTMENT FUND | 71,868 | 0 | 0 | 0 | For |
Showing the 25 largest of 64 asset managers. All 64 are in the interactive database (link above).
Meeting held June 20, 2024.
Combines 15 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 99.1% for (June 8, 2023 meeting) ▼ 0.4 pts
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION ("SAY-ON-PAY").
REVOLUTION MEDICINES INC.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 128,861,403 for, 1,624,748 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,232,107 | 0 | 0 | 0 | For |
| BlackRock | 6,608,389 | 0 | 0 | 0 | For |
| Fidelity | 5,793,508 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,734,343 | 0 | 0 | 0 | For |
| State Street | 2,351,818 | 551 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,192,696 | 0 | 0 | 0 | For |
| JPMorgan | 2,096,349 | 0 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| Dimensional | 826,675 | 0 | 0 | 0 | For |
| Hartford | 758,858 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 708,697 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 650,826 | 0 | 0 | 0 | For |
| Victory Capital | 461,640 | 0 | 0 | 0 | For |
| Equitable | 388,608 | 0 | 0 | 0 | For |
| TIAA | 363,923 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 272,401 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 260,003 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,318 | 0 | 0 | 0 | For |
| John Hancock | 199,845 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 183,868 | 0 | 0 | 0 | For |
| Voya | 164,067 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,888 | 0 | 0 | 0 | For |
| Lincoln Financial | 140,761 | 0 | 0 | 0 | For |
| Jackson National | 120,029 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 115,256 | 0 | 0 | 0 | For |
Fund voting reports, all 70 managers: 53,291,935 for, 25,727 against, 11,061 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| New York Life | 17,000,000 | 0 | 0 | 0 | For |
| Wellington | 13,261,836 | 0 | 0 | 0 | For |
| BVF INC/IL | 5,981,212 | 0 | 0 | 0 | For |
| Nextech Invest Ltd. | 5,761,628 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT LLC | 5,087,354 | 0 | 0 | 0 | For |
| State Street | 4,897,123 | 551 | 0 | 0 | For |
| T. Rowe Price | 4,768,758 | 0 | 0 | 0 | For |
| BlackRock | 4,612,593 | 16,257 | 0 | 0 | For |
| Fidelity | 4,217,402 | 0 | 0 | 0 | For |
| Janus Henderson | 4,209,071 | 0 | 0 | 0 | For |
| Boxer Capital, LLC | 3,675,582 | 0 | 0 | 0 | For |
| Woodline Partners LP | 3,399,131 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,090,073 | 0 | 0 | 0 | For |
| JPMorgan | 3,061,075 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,051,710 | 0 | 0 | 0 | For |
| AH Capital Management, L.L.C. | 2,128,523 | 0 | 0 | 0 | For |
| Holocene Advisors, LP | 1,258,003 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,135,800 | 0 | 0 | 0 | For |
| Northern Trust | 1,101,194 | 99 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 991,479 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 958,014 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 906,390 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 826,905 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 764,981 | 0 | 0 | 0 | For |
Institutional-manager reports, all 200 managers: 107,240,089 for, 1,143,683 against, 2,327 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 20, 2024.
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (June 8, 2023 meeting) unchanged
Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024; and
REVOLUTION MEDICINES INC.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 148,105,275 for, 9,895 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 53,317,724 for, 11,061 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 22,232,107 | 0 | 0 | 0 | For |
| BlackRock | 6,608,389 | 0 | 0 | 0 | For |
| Fidelity | 5,793,508 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,734,343 | 0 | 0 | 0 | For |
| State Street | 2,352,369 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,192,696 | 0 | 0 | 0 | For |
| JPMorgan | 2,096,349 | 0 | 0 | 0 | For |
| Charles Schwab | 1,057,860 | 0 | 0 | 0 | For |
| Dimensional | 826,675 | 0 | 0 | 0 | For |
| Hartford | 758,858 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 708,697 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 650,826 | 0 | 0 | 0 | For |
| Victory Capital | 461,640 | 0 | 0 | 0 | For |
| Equitable | 388,608 | 0 | 0 | 0 | For |
| TIAA | 363,923 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 272,401 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 260,003 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,318 | 0 | 0 | 0 | For |
| John Hancock | 199,845 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 183,868 | 0 | 0 | 0 | For |
| Voya | 164,067 | 0 | 0 | 0 | For |
| Northwestern Mutual | 152,888 | 0 | 0 | 0 | For |
| Lincoln Financial | 140,761 | 0 | 0 | 0 | For |
| Jackson National | 120,029 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 115,256 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 164,913,014 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 13.48% |
| 2 | BlackRock | 4.01% |
| 3 | Fidelity | 3.51% |
| 4 | T. Rowe Price | 2.26% |
| 5 | State Street | 1.43% |
| 6 | JANUS INVESTMENT FUND | 1.33% |
| 7 | JPMorgan | 1.27% |
| 8 | Charles Schwab | 0.64% |
| 9 | Dimensional | 0.50% |
| 10 | Hartford | 0.46% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | New York Life | 10.31% |
| 2 | Wellington | 8.04% |
| 3 | BVF INC/IL | 3.63% |
| 4 | Nextech Invest Ltd. | 3.49% |
| 5 | FARALLON CAPITAL MANAGEMENT LLC | 3.08% |
| 6 | State Street | 2.97% |
| 7 | T. Rowe Price | 2.89% |
| 8 | BlackRock | 2.81% |
| 9 | Fidelity | 2.56% |
| 10 | Janus Henderson | 2.55% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Vanguard Group | 15,663,094 | 9.50% | Form 13F, quarter ended March 31, 2024 |
| Entities affiliated with Wellington Management Group | 14,882,086 | 9.02% | Proxy statement (DEF 14A), table as of March 31, 2024 |
| Wellington Management | 14,714,726 | 8.92% | Form 13F, quarter ended March 31, 2024 |
| FMR (Fidelity) | 9,401,687 | 5.70% | Form 13F, quarter ended March 31, 2024 |
| BlackRock | 8,327,758 | 5.05% | Form 13F, quarter ended March 31, 2024 |
| Thilo Schroeder, Ph.D. | 6,487,458 | 3.93% | Proxy statement (DEF 14A), table as of March 31, 2024 |
| State Street | 5,386,020 | 3.27% | Form 13F, quarter ended March 31, 2024 |
| T. Rowe Price | 4,814,310 | 2.92% | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 3,052,691 | 1.85% | Form 13F, quarter ended March 31, 2024 |
| Alexis Borisy | 2,622,333 | 1.59% | Proxy statement (DEF 14A), table as of March 31, 2024 |
Percentages above are of 164,913,014 shares outstanding, as reported by REVOLUTION MEDICINES INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At REVOLUTION MEDICINES INC.'s 2 shareholder meetings in the 2023-2024 proxy season (held November 8, 2023 and June 20, 2024), 247 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 2,101 separate fund positions. On the most widely held item of the season, voted at the meeting held June 20, 2024 — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — REVOLUTION MEDICINES INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REVOLUTION MEDICINES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REVOLUTION MEDICINES INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
REVOLUTION MEDICINES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “REVOLUTION MEDICINES (RVMD) 2023-2024 Annual & Special Meetings”, https://proxyvotesnow.com/company/revolution-medicines-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.